Using an in vitro drug screening approach, we found that ESK440 significantly inhibits proliferation of cancer cells with different types of ALK genomic aberrations such as lung cancer cells (EML4-ALK fusion) and NB cells (mutations, amplifications), as well as some of the DIPG cells (Fig. 1). Here, EML4 is linked to lung cancer.